Since Luc90-CAR-T shows potent anti-myeloma activity against OPM2-CG and MM.1 S cell lines that endogenously express CS1, we predicted it would efficiently bind to human myeloma cells. Here, SLAMF7 is linked to plasma cell myeloma.